Document:

Rule 10b5-1 Sales Plan dated March 17, 2006

 EXHIBIT 10.1 
 

 
 Rule 10b5-1 Trading Plan 
 John D. Held (“Seller”) adopts this Trading Plan dated March 17, 2006 (the “Trading Plan”) with respect to the “Stock” (defined below) with UBS Financial Services Inc. for the
purpose of establishing a trading plan that complies with Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 
 Seller and UBS Financial Services Inc. agree as follows: 
  

	1.	Specific Plan of Sale. UBS Financial Services Inc., acting as agent, agrees to effect sales of Stock on behalf of Seller in accordance with the specific instructions set
forth in Exhibit A (the “Sales Instructions”). The term “Stock” means the common stock, par value $0.01 per share, of Omega Protein Corporation (“Issuer”) (symbol: OME), including Stock that Seller has the right to
acquire under the outstanding stock options issued by Issuer listed on Exhibit D (the “Options”), and includes any class or series of common stock of Issuer into which the Stock is converted whether pursuant to a reclassification,
reorganization, reincorporation or similar event. 

  

	2.	Fees/Commissions. Seller shall pay UBS Financial Services Inc. $0.05 per share of Stock sold; with such amounts to be deducted by UBS Financial Services Inc. from the
proceeds of sales under this Trading Plan. 

  

	3.	Seller’s Representations and Warranties. Seller represents and warrants that: 

  

	 	(a)	Seller is not aware of any material nonpublic information concerning Issuer or any securities of Issuer; 

  

	 	(b)	Seller is entering into this Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1; 

  

	 	(c)	Seller has informed Issuer of this Trading Plan and has furnished Issuer with a copy, and Seller has determined that this Trading Plan is consistent with Issuer’s insider
trading policy; 

  

	 	(d)	Seller has disclosed to UBS Financial Services Inc. any agreements that Seller is currently party to, or within the past 60 days, has been party to, with another broker, dealer or
financial institution (each, a “Financial Institution”) entered into for the purpose of establishing a trading plan that complies with Rule 10b5-1; 

  

	 	(e)	Seller is not subject to any legal, regulatory or contractual restriction or undertaking that would prevent UBS Financial Services Inc. from conducting sales in accordance with this
Trading Plan; 

  

	 	(f)	the Stock to be sold under this Trading Plan is owned free and clear by Seller and is not subject to any liens, security interests or other encumbrances or limitations on
dispositions, other than those imposed by Rule 144 or Rule 145, if applicable; 

  

	 	(g)	Seller has had an opportunity to consult with Seller’s own advisors as to the legal, tax, financial and other aspects of this Trading Plan, including this Trading Plan’s
compliance with Rule 10b5-1 and applicable state law. Seller has not received or relied on any representations from UBS Financial Services Inc. concerning this Trading Plan’s compliance with Rule 10b5-1. 

  

	4.	Agreements by Seller. Seller acknowledges and agrees to the following provisions: 

  

	 	(a)	Brokerage Account. Seller shall open a sole-purpose UBS Financial Services Inc. brokerage account prior to the execution of sales under this Trading Plan in the name of and
for the benefit of Seller (the “Plan Account”). 

  

	 	(b)	Delivery of Stock. Seller shall deliver all shares of Stock to be sold pursuant to this Trading Plan into the Plan Account prior to the commencement of any sales under this
Trading Plan. 

  

	 	(c)	Hedging Transactions. While this Trading Plan is in effect, Seller shall comply with the prohibition set forth in Rule 10b5-1(c)(1)(i)(C) against entering into or
altering a corresponding or hedging transaction or position with respect to the Stock. 

	 	(d)	Notice to UBS Financial Services Inc.. Seller shall notify UBS Financial Services Inc. to terminate or suspend sales, as appropriate, as soon as practicable upon the
occurrence of any of the events contemplated in paragraph 7(a) or (b) or paragraph 8(c). 

  

	 	(e)	Communications. Seller shall not, directly or indirectly, communicate any material nonpublic information relating to the Stock or Issuer to any employee of the UBS Financial
Services Inc. 10b5-1 Group or any UBS Financial Services Inc. Financial Advisor. 

  

	 	(f)	Compliance with Applicable Laws and Required Exchange Act Filings. Seller shall comply with all applicable laws, rules and regulations, and Seller shall make all filings
required under Sections 13 and 16 of the Exchange Act in a timely manner. 

  

	 	(g)	No Influence. Seller does not have, and shall not attempt to exercise, any influence over how, when or whether to effect sales of Stock pursuant to this Trading Plan.

  

	 	(h)	Stock Non-Marginable. The Stock is not marginable and may not be used by Seller as collateral for any purpose. 

  

	 	(i)	Execution, Average Pricing and Pro Rata Allocation of Sales. UBS Financial Services Inc. may sell Stock on any national securities exchange, in the over-the-counter market,
on an automated trading system or otherwise. UBS Financial Services Inc. or one of its affiliates may make a market in the Stock and may act as principal in executing sales under the Trading Plan. To the extent that UBS Financial Services Inc.
administers other trading plans relating to Issuer’s securities, UBS Financial Services Inc. may aggregate orders for Seller with orders under other sellers’ trading plans for execution in a block and allocate each execution on a pro rata
basis to each seller. In the event of partial execution of block orders, UBS Financial Services Inc. shall allocate the proceeds of all Stock actually sold on a particular day pursuant to all Rule 10b5-1 trading plans concerning Issuer’s
securities that UBS Financial Services Inc. manages pro rata based on the ratio of (x) the number of shares to be sold pursuant to the order instructions of each Trading Plan to (y) the total number of shares to be sold under all Trading
Plans having the same type of order instructions. 

  

	 	(j)	Exclusivity. Until this Trading Plan has been terminated, Seller shall not enter into any agreement with, give any instructions to, or adopt a plan for trading with another
Financial Institution with respect to purchase or sale of the Stock or the Options for the purpose of establishing a trading plan that complies with Rule 10b5-1. 

  

	 	(k)	Acknowledgment of Relief from Obligation to Effect Sales. UBS Financial Services Inc. shall be relieved of its obligation to sell Stock as otherwise required by
paragraph 1 above at any time when: 

  

	 	(i)	UBS Financial Services Inc. has determined that (A) it is prohibited from doing so by a legal, contractual or regulatory restriction applicable to it or its affiliates or to
Seller or Seller’s affiliates; or (B) a material adverse change in the financial markets, in the market activity in the Stock or in the internal systems of UBS Financial Services Inc. or one of its affiliates, an outbreak or escalation of
hostilities or other crisis or calamity has occurred (in each case, the effect of which is such as to make it, in the sole judgment of UBS Financial Services Inc., impracticable for UBS Financial Services Inc. to sell Stock); or (C) a trading
suspension with respect to the Stock by the Securities and Exchange Commission or the Principal U.S. Market (defined in Exhibit A) or a delisting of the Stock or a banking moratorium has occurred; if UBS Financial Services Inc. cannot effect a sale
for any of such reasons, UBS Financial Services Inc. shall effect such sale as promptly as practical after the cessation or termination of such cause, subject to the restrictions set forth in paragraph 1 of Exhibit A;

  

	 	(ii)	This Trading Plan is suspended in accordance with paragraph 7 below; 

  

	 	(iii)	This Trading Plan is terminated in accordance with paragraph 8 below; 

  

	5.	Rule 144 and Rule 145. With respect to sales of Stock subject to Rule 144 or Rule 145, Seller and UBS Financial Services Inc. agree to comply with the
following provisions: 

  

	 	(a)	Agreements by Seller Regarding Rule 144 and Rule 145. 

  

	 	(i)	Seller agrees not to take, and agrees to cause any person or entity with which Seller would be required to aggregate sales of Stock pursuant to Rule 144(a)(2) or (e) not
to take, any action that would cause the sales hereunder not to meet all applicable requirements of Rule 144 or Rule 145. 

	 	(ii)	Seller agrees to complete, execute and deliver to UBS Financial Services Inc. Forms 144 for sales to be effected under the Trading Plan at such times and in such numbers as UBS
Financial Services Inc. shall request. Seller hereby grants UBS Financial Services Inc. a power of attorney to complete and file on behalf of Seller any required Forms 144. The remarks section of each Form 144 filed shall include a statement to
the effect that the shares covered by the Form 144 are being sold pursuant to a Rule 10b5-1 trading plan dated as of the date hereof, and the representation regarding the seller’s knowledge of material nonpublic information speaks as
of that plan adoption date. 

  

	 	(iii)	Seller agrees to complete, execute and deliver to UBS Financial Services Inc. Rule 144 Seller’s Representation Letters (in the form attached as Exhibit C) for sales
to be effected under the Trading Plan at such times and in such numbers as UBS Financial Services Inc. shall request. 

  

	 	(b)	Agreements by UBS Financial Services Inc. Regarding Rule 144 and Rule 145. 

  

	 	(i)	UBS Financial Services Inc. agrees to conduct all sales pursuant to the Trading Plan in accordance with the manner of sale requirement of Rule 144. UBS Financial Services Inc.
shall not effect any sales that it knows would exceed the then-applicable volume limitation under Rule 144. 

  

	 	(ii)	UBS Financial Services Inc. agrees to file such Forms 144 furnished by Seller pursuant to paragraph 5(a)(ii) on behalf of Seller as required by applicable law. UBS Financial
Services Inc. shall make one Form 144 filing at the beginning of each three-month period, commencing upon the first Sale Day under the Trading Plan. 

  

	 	(iii)	UBS Financial Services Inc. agrees to submit such Rule 144 Seller’s Representation Letters furnished by Seller pursuant to paragraph 5(a)(iii) on behalf of Seller as
required by Issuer’s transfer agent. 

  

	 	(iv)	Seller shall make and shall be solely responsible for all filings required under Sections 13(d) and 16 of the Exchange Act in connection with sales of Stock pursuant to the
Trading Plan, and Seller acknowledges that UBS Financial Services Inc. shall not make any such filings and shall have no liability to Seller in connection with or related to any such filings. 

  

	6.	Options. Seller and UBS Financial Services Inc. agree to the provisions regarding the exercise of Options contained in Exhibit D. 

  

	7.	Suspension. Sales under this Trading Plan shall be suspended as follows: 

  

	 	(a)	Promptly after the date on which UBS Financial Services Inc. receives notice from Seller or Issuer of legal, contractual or regulatory restrictions applicable to Seller or
Seller’s affiliates that would prevent UBS Financial Services Inc. from selling Stock under this Trading Plan (such notice merely stating that there is a restriction applicable to Seller without specifying the reasons for the restriction),
including a restriction based on Seller’s awareness of material nonpublic information in connection with a tender offer for Issuer’s securities (transactions on the basis of which Rule 14e-3 of the Exchange Act could be violated).

  

	 	(b)	In the event of a Qualifying Securities Offering, promptly after the date on which UBS Financial Services Inc. receives notice from Issuer or Seller of the Suspension Date until UBS
Financial Services Inc. receives notice from Issuer or Seller of the Resumption Date; provided, however, that (i) Seller certifies that Seller has no control over the Suspension Date or the Resumption Date, and (ii) if Seller is unable to
make such certification then this paragraph shall result in a termination of the Trading Plan, rather than suspension. 

 “Qualifying Securities Offering” means any offering of securities of Issuer for cash in which the lead underwriter, lead manager, initial purchaser, placement agent or other entity performing a similar function (each, an
“Underwriter”) requires Seller to agree to restrict Seller’s ability to effect Sales pursuant to this Trading Plan. 
 “Suspension Date” means the date on which a preliminary prospectus, offering memorandum, offering circular or other disclosure document (each, a “Preliminary Offering Document”) is first 

 used to market securities of Issuer by the Underwriter, or if a Preliminary Offering Document is not
used, the date on which the underwriting agreement, purchase agreement, placement agent agreement or similar agreement (each, an “Underwriting Agreement”) is entered into by the Underwriter and Issuer. 
 “Resumption Date” means the day immediately following the expiration of the time period during which Seller was restricted from effecting Sales
pursuant to this Trading Plan in accordance with the Underwriting Agreement. 
  

	 	(c)	In the event that the UBS Financial Services Inc. 10b5-1 Group becomes aware of material nonpublic information concerning Issuer or the Stock, UBS Financial Services Inc. may be
required by applicable law or, in its sole discretion, find it advisable, to suspend sales under this Trading Plan. In such case, UBS Financial Services Inc. shall promptly notify Seller of the suspension of sales under this Trading Plan.

  

	8.	Termination. This Trading Plan will terminate on the earliest to occur of the following (the “Plan Sales Period”): 

  

	 	(a)	at the close of trading on March 15, 2008; 

  

	 	(b)	promptly after the date on which UBS Financial Services Inc. receives notice from Seller of the termination of this Trading Plan, in which case, Seller agrees to notify the Issuer
promptly of such termination; 

  

	 	(c)	upon the reasonable determination by UBS Financial Services Inc., or promptly after the reasonable determination by Seller and notice to UBS Financial Services Inc., that this
Trading Plan does not comply with Rule 10b5-1; 

  

	 	(d)	promptly after the date UBS Financial Services Inc. is notified of the death of Seller; 

  

	 	(e)	immediately in the event that Seller fails to deliver any Stock pursuant to paragraph 4(b) or fails to satisfy the delivery requirements with respect to Options set forth in
Exhibit D; or 

  

	 	(f)	the date that the aggregate number of shares of Stock sold pursuant to this Trading Plan reaches 128,600 shares. 

  

	9.	Indemnification; Limitation of Liability. 

  

	 	(a)	Indemnification. 

  

	 	(i)	Seller agrees to indemnify and hold harmless UBS Financial Services Inc. and its directors, officers, employees and affiliates from and against all claims, losses, damages and
liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) (collectively, “Losses”) arising out of or attributable to (A) UBS
Financial Services Inc.’s actions taken or not taken in compliance with this Trading Plan, (B) any breach by Seller of this Trading Plan (including Seller’s representations and warranties hereunder), or (C) any violation by
Seller of applicable laws or regulations. This indemnification shall survive termination of this Trading Plan. 

  

	 	(ii)	UBS Financial Services Inc. agrees to indemnify and hold harmless Seller from and against all Losses arising out of or attributable to the gross negligence or willful misconduct of
UBS Financial Services Inc. in connection with this Trading Plan. 

	 	(b)	Limitation of Liability. 

  

	 	(i)	Notwithstanding any other provision hereof, UBS Financial Services Inc. shall not be liable to Seller, and Seller shall not be liable to UBS Financial Services Inc., for:
(A) special, indirect, punitive, exemplary or consequential damages, or incidental losses or damages of any kind, even if advised of the possibility of such losses or damages or if such losses or damages could have been reasonably foreseen; or
(B) any failure to perform or to cease performance or any delay in performance that results from a cause or circumstance that is beyond its reasonable control, including, but not limited to, failure of electronic or mechanical equipment,
strikes, failure of common carrier or utility systems, severe weather, market disruptions or other causes commonly known as “acts of God”. 

  

	 	(ii)	Notwithstanding any other provision hereof, UBS Financial Services Inc. shall not be liable to Seller for (A) the exercise of discretionary authority or discretionary control
under this Trading Plan, if any, or (B) any failure to effect a sale required by paragraph 1, except for failures to effect sales as a result of the gross negligence or willful misconduct of UBS Financial Services Inc.

  

	10.	Agreement to Arbitrate. Any dispute between Seller and UBS Financial Services Inc. arising out of, relating to or in connection with this Trading Plan or any transaction
relating to this Trading Plan shall be determined only by arbitration as provided in the UBS Financial Services Inc. brokerage account agreement referred to in paragraph 4(a). 

  

	11.	Notices. 

  

	 	(a)	All notices to UBS Financial Services Inc. under this Trading Plan shall be provided in writing to the Executive Services Group of UBS Financial Services Inc. by facsimile at fax
number 615-332-6809. 

  

	 	(b)	All notices to Seller under this Trading Plan shall be given to John D. Held by telephone at telephone number 713-940-6116, by facsimile at fax number 713-940-6122 or by certified
mail to the address below: 

  

							
		  	2101 City West Blvd.	  		  	
		  	Building 3 Suite 500	  		  	
		  	Houston, Texas 77042	  		  	

  

	 	(c)	Seller hereby instructs and authorizes UBS Financial Services Inc. to send duplicate copies of all confirmations of trades made under this Trading Plan to the Issuer at the
following address: 

  

							
		  	Jude Brinkman	  		  	
		  	Omega Protein Corporation	  		  	
		  	2101 City West Blvd.	  		  	
		  	Building 3 Suite 500	  		  	
		  	Houston, Texas 77042	  		  	

  

	 	(d)	UBS Financial Services Inc. will provide notification of all sales of Stock and exercise of Options under this Trading Plan to Seller and to Issuer by e-mail at the below addresses
by 6 p.m. (ET) on the date of execution on a best efforts basis, with a final report by 12 p.m. (ET) on the following business day. Seller and Issuer agree to notify UBS Financial Services Inc. in writing of any changes to the contact information
provided. 

  

							
		  	    johndheld@msn.com	  		  	
		  	    jbrinkman@omegaproteininc.com	  		  	

  

	12.	Amendments and Modifications. This Trading Plan and the Exhibits hereto may be amended by Seller only upon the written consent of UBS Financial Services Inc. and receipt by
UBS Financial Services Inc. of the following documents, each dated as of the date of such amendment: 

  

	 	(a)	a certificate signed by Seller, certifying that the representations and warranties of Seller contained in this Trading Plan are true at and as of the date of such certificate as if
made at and as of such date; and 

	 	(b)	an issuer certificate completed by Issuer substantially in the form of Exhibit B. 

  

	13.	Inconsistency with Law. If any provision of this Trading Plan is or becomes inconsistent with any applicable present or future law, rule or regulation, that provision will be
deemed modified or, if necessary, rescinded in order to comply with the relevant law, rule or regulation. All other provisions of this Trading Plan will continue and remain in full force and effect. 

  

	14.	Governing Law. This Trading Plan shall be governed by and construed in accordance with the internal laws of the State of New York. 

  

	15.	Entire Agreement. This Trading Plan, including Exhibits, and the brokerage account agreement referred to in paragraph 4(a) above, constitute the entire agreement between
the parties with respect to this Trading Plan and supercede any prior agreements or understandings with regard to this Trading Plan. 

  

	16.	Counterparts. This Trading Plan may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto
were upon the same instrument. 

 NOTICE: THIS AGREEMENT CONTAINS A PREDISPUTE ARBITRATION CLAUSE IN
PARAGRAPH 10. 
 IN WITNESS WHEREOF, the undersigned have signed this Trading Plan as of the date first written above.

  

							
	JOHN D. HELD	 		 	
			
	 /s/ John D. Held
	 		 	March 17, 2006
	Name:	 	John D. Held	 		 	Date
	Title:	 	General Counsel, Executive Vice President and Secretary	 		 	
			
	UBS FINANCIAL SERVICES INC.	 		 	
			
	  
	 		 	  

	Name:	 	Doug Jones	 		 	Date
	Title:	 	Corporate Vice President	 		 	
			
	  
	 		 	  

	Name:	 	Ed Lynn	 		 	Date
	Title:	 	Senior Vice PresidentLicense Development and Supply Agreement

 Exhibit 10.54 
 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT 
 THIS LICENSE, DEVELOPMENT
AND SUPPLY AGREEMENT (the “Agreement”), dated as of November 23, 2005, (the “Effective Date”) entered into between SICOR PHARMACEUTICALS, INC., a Delaware corporation (“Teva / Sicor”), having a place of
business located at 19 Hughes, Irvine, California 92618, and ANTARES PHARMA, INC., a Delaware corporation (“Antares”), having a place of business located at 707 Eagleview Boulevard, Suite 414, Exton, Pennsylvania 19341, 
 WITNESSETH: 
 WHEREAS,
Antares owns or has rights to certain technology which may be used in the manufacture of ****; and 
 WHEREAS, Antares and Teva
/ Sicor desire to collaborate in the development and commercialization of the Device on the terms and subject to the conditions set forth below; and 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 For purposes of this Agreement, the terms defined in this Article 1 have the meanings set forth below: 
 1.1 “Affiliate” means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under
common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least fifty percent (50%) of the voting stock or other ownership interest of the other Person,
provided that such entity shall be considered an Affiliate only for the time during which such control exists. 
 1.2 “ANDA”
means an Abbreviated New Drug Application for the Product which has been or will be submitted to the FDA pursuant to 21 U.S.C. § 355(j) and the regulations promulgated by the FDA thereunder, including any amendments or supplements thereto.

 1.3 “Antares Patent Rights” means all issued patents and patent applications, divisionals, continuations,
continuations-in-part, reissues, renewals, extensions or additions to any such patent applications or patents heretofore or hereafter filed in any country in the 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
Territory owned by or licensed to Antares or to which Antares otherwise acquires rights, which claim the Device, or the process of manufacture or use of the
Device in the Territory. 
 1.4 “ASP” means Teva / Sicor’s average Net Sales price for a single unit of the Product
during a calendar quarter. 
 1.5 “cGMP” means current Good Manufacturing Practices as promulgated by the FDA and set forth
in 21 CFR Parts 210 and 211. 
 1.6 “Change of Control” shall mean, with respect to the applicable Party, an event where:
(a) any Third Party (alone or together with such Third Party’s Affiliates) or “group” (as such term is defined under Section 13(d) of the Securities Exchange Act of 1934, as amended) (i) acquires beneficial ownership of
capital stock of such Party entitling the holder(s) thereof to greater than fifty percent (50%) of the voting power of the then outstanding capital stock of such Party with respect to the election of directors of such Party, or
(ii) otherwise actually controls or is in a controlling position with respect to the voting power of the then outstanding capital stock of such Party; or (b) such Party consummates a merger, consolidation, reorganization or similar
transaction or series of related transactions, whether direct or indirect, with another Third Party, alone or together with such Third Party’s Affiliates (the “Acquiring Corporation”), in which: (i) such Party is not the
surviving corporation in such transaction, (ii) the members of the Board of Directors of such Party prior to such transaction constitute less than one half of the members of the Board of Directors of the Acquiring Corporation following such
transaction, (iii) greater than fifty percent (50%) of the voting power of the outstanding capital stock of the Acquiring Corporation with respect to the election of directors following such transaction is held by Third Parties who were
shareholders of the Acquiring Corporation prior to such transaction, or (iv) such Party is otherwise effectively controlled by the Acquiring Corporation, or (c) such Party sells to any Third Party(s) (alone or together with such Third
Party’s Affiliates) in one or more related transactions properties or assets representing greater than fifty percent (50%) of: (i) such Party’s consolidated total assets as reflected on its most recent annual audited financial
statements, provided that all or substantially all of the properties and assets used in connection with such Party’s pharmaceutical business are included in such transaction(s), or (ii) such Party’s pharmaceutical business.
Notwithstanding anything to the contrary in this definition, a Change of Control shall not be deemed to have occurred with respect to a Party where any acquisition, merger, consolidation, reorganization, sale or similar transaction occurs solely
between such Party and any one or more of its Affiliates. 
 1.7 “Confidential Information” means any invention, discovery,
patent application or claim, trade secret, idea, improvement or other work of authorship, any process, formula, data, clinical trial data, program, drawing, information, price, technique, sample, compound, extract, media, vector or cell line and
procedures and formulations or drawings for producing any such sample, compound, extract, media, vector or cell line, any process, formula or data relating to any research project, work in process, future development, engineering, manufacturing,
marketing, servicing, financing or personnel matter relating to a Party, its present or future products, sales suppliers, clients, customers, employees, investors, or business, whether in oral, written, graphic, physical or electronic form.

 1.8 “Contract Margin” means ****. 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 1.9 “Device” means **** 
 1.10 “Drug” means ****. 
 1.11 “FDA” means the United States Food and Drug Administration. 
 1.12 “Field” means
****. 
 1.13 “Know-How” means all information and data, including formulas, procedures, protocols, techniques and
results of experimentation and testing, which are necessary or useful to make, use, develop, sell or seek regulatory approval in the Territory to market the Product, which Antares owns or controls, has the right to license to Teva / Sicor, and which
is in the possession of Antares on the Effective Date of this Agreement or thereafter during the term of this Agreement. 
 1.14
“Licensed Technology” means the Antares Patent Rights together with all improvements to the Licensed Technology relating to the Device developed by Antares during the term of this Agreement. 
 1.15 **** 
 1.16 “Net
Sales” means, with respect to Product sold by Teva / Sicor or its Affiliates to Third Parties, **** 
 1.17 “Paragraph III
Certification” means a certification pursuant to section 505(j)(2)(A)(vii)(III) of the Food, Drug and Cosmetic Act, 21 U.S.C. § 355(j)(2)(A)(vii)(III). 
 1.18 “Party” means either Antares or Teva / Sicor respectively. 
 1.19
“Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization,
governmental authority or any other form of entity specifically listed herein. 
 1.20 “Product” means any product
comprising the Device and the Drug. 
 1.21 “QSR” means the Quality System Regulation as promulgated by the FDA and set
forth in 21 CFR Part 820. 
 1.22 “Teva / Sicor Patent Rights” means all issued patents and patent applications,
divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such patent applications or patents heretofore or hereafter filed in any country in the Territory owned by or licensed to Teva / Sicor or any of
its Affiliates or to which Teva / Sicor or any of its Affiliates otherwise acquires rights, which claim the Drug, or the process of manufacture or use of the Drug in the Territory. 
 1.23 “Territory” means the United States of America, including its territories, possessions and the Commonwealth of Puerto Rico.

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 1.24 “Third Party” means any Person other than Teva / Sicor, Antares and their
respective Affiliates. 
 1.25 “Unit Price” means Teva / Sicor’s purchase price for a single unit of the Device.

 ARTICLE 2 
 REPRESENTATIONS
AND WARRANTIES 
 2.1 Representations by Each Party. Each Party hereby represents and warrants to the other Party, as of the
execution of this Agreement, as follows: 
 2.1.1 Corporate Existence and Power. Such Party (a) is a corporation
duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated; (b) has the corporate power and authority and the legal right to own and operate its property and assets, to lease the
property and assets it operates under lease, and to carry on its business as it is now being conducted; and (c) is in compliance with all requirements of applicable law, except to the extent that any noncompliance would not have a material
adverse effect on the properties, business, financial or other condition of such Party and would not materially adversely affect such Party’s ability to perform its obligations under this Agreement. 
 2.1.2 Authorization and Enforcement of Obligations. Such Party (a) has the corporate power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. The
Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms. 
 2.1.3 Consents. All necessary consents, approvals and authorizations of all governmental authorities and other Persons required to
be obtained by such Party in connection with this Agreement have been obtained. 
 2.1.4 No Conflicts. The execution
and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a default
under, any contractual obligation of such Party. 
 2.2. Representations of Antares. Antares hereby represents and warrants to Teva /
Sicor that Antares is either in sole possession of or otherwise possesses all necessary consents, approvals and authorizations to the Licensed Technology to grant the license set forth in Article 3 hereof to Teva / Sicor. 
 ARTICLE 3 
 LICENSE GRANT 
 3.1 License. Subject to the terms and conditions of this Agreement, during the term of this Agreement, Antares hereby grants to Teva / Sicor and
its Affiliates an exclusive license (exclusive even as to Antares), with the right to sublicense (subject to the provisions of section 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
3.2), under the Antares Patent Rights and Know How to use the Device in the Product and to sell, offer for sale, import and distribute the Product in the
Field in the Territory. 
 3.2 Sublicenses. Teva / Sicor may grant sublicenses in the Territory, provided that Teva / Sicor shall
ensure all such sublicensees assume and comply with all terms and conditions under which Teva / Sicor is obligated as a licensee under this Agreement. Teva / Sicor shall indemnify and hold Antares harmless from any cost, liability, or damage arising
from any sublicensee’s failure to so comply. Teva / Sicor shall pay Antares ****. 
 3.3 Exclusivity. Subject to the
provisions of section 10.2.3 hereof, during the term of this Agreement, neither Party or any of its Affiliates, either alone or through any Third Party, will develop, manufacture for use in the Field and the Territory or commercialize any device or
product comprised of **** which competes with the Product in the Field and the Territory except pursuant to this Agreement. 
 3.4 Right
of First Refusal. Antares shall promptly notify Teva / Sicor in writing before offering a license to the Device for use in the Field to a Third Party in a country outside the Territory. Teva / Sicor shall have thirty (30) days from receipt
of such notice in which to negotiate a non-binding term sheet with Antares for an exclusive license to the Device for use in the Field in such country or countries. If the parties are unable to reach agreement on such non-binding terms within such
thirty (30) day period, Antares may negotiate and execute a license with a Third Party, but not on terms any less favorable to Antares than the terms last offered by Teva / Sicor. If the Parties agree in writing to such non-binding terms within
such thirty (30) day period, Teva / Sicor shall have sixty (60) days following immediately from such thirty (30) day period in which to negotiate and enter into an exclusive license with Antares for the Device in such country or
countries, as the case may be. All negotiations shall be conducted in good faith. If the parties do not enter into such a license within such sixty (60) day period, Antares may negotiate and execute a license with a Third Party, but not on
terms any less favorable to Antares than the terms last offered by Teva / Sicor. 
 3.5 Additional License in the Event of Failure to
Supply. In the event that Antares is unable to supply conforming Devices to Teva / Sicor in connection with an accepted purchase order pursuant to Article 5 hereof, with such failure remaining uncured for thirty (30) days, then Antares
hereby grants to Teva / Sicor a royalty-bearing right and license in the Territory to (i) make and have made the Device for use in the Product in the Field in the Territory, and (ii) use and reference the necessary regulatory
documentation, and any and all data or information included or referenced therein, to make or have made the Device. For any Device manufactured by Teva / Sicor pursuant to this Section, Teva / Sicor shall pay Antares the royalties due under
Section 7.1 hereof. If thereafter Antares notifies Teva/Sicor that Antares is able to supply conforming Devices again pursuant to Article 5 hereof, then Antares shall provide notice of the same to Teva / Sicor and Antares shall resume its
supply of Devices as provided in this Agreement. Upon Antares’ resumption of such supply, the foregoing license granted to Teva / Sicor in this Section shall immediately terminate and be of no further force or effect. 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 ARTICLE 4 
 DEVELOPMENT PROGRAM AND MILESTONE PAYMENTS 
 4.1 Development Program. Promptly upon execution
of this Agreement, the Parties shall commence a development program (the “Program”), which shall be designed to complete the Device development and to scale-up the Device for commercial production for use with the Drug in the Product. The
Program will include finalizing a Product specification **** Once the Product specifications are finalized by agreement of the Parties, any additional changes to the Device requested by Teva / Sicor must be agreed to by Antares. Teva / Sicor will
provide Antares with all change requests in writing. Antares will provide Teva / Sicor with an estimate of cost and time required to implement any changes, and Teva / Sicor will be responsible for all such costs. 
 4.1.1 Antares’ Responsibilities. Antares will be responsible for **** Antares will maintain **** any other required
regulatory submissions and approvals, in good standing, and maintain its facilities in compliance with QSR. 
 4.1.2 Teva /
Sicor’s Responsibilities. Once the Product specifications are finalized, Teva / Sicor will be responsible for **** 
 4.1.3 Additional Costs. Any costs incurred by Antares to accelerate the Program at the request of Teva / Sicor will be borne by Teva / Sicor. Any increased costs directly related to development of the **** Product incurred by
Teva / Sicor as a result of delays in the development or scale-up of the Device due to Antares’ failure to meet their obligations in the schedule set forth in the Program will be borne by Antares. 
 4.2 Payments By Teva / Sicor. 
 4.2.1 Payments Upon Execution of This Agreement. Upon the execution and delivery of this Agreement, Teva / Sicor shall pay to Antares the sum of (a) five hundred thousand dollars ($500,000) in exchange for 400,000 shares of Antares
common stock, subject to the Stock Purchase Agreement executed by the Parties contemporaneously herewith and attached as Exhibit “A” hereto ; and **** in exchange for the exclusive license set forth in Section 3.1 hereof.

 4.2.2 Milestone Payment. Upon final FDA approval of the Product, Teva / Sicor shall pay to Antares the sum of ****

 4.2.3 **** 
 ARTICLE 5 
 COMMERCIAL SUPPLY OF DEVICE 
 5.1 Device Supply. Upon FDA approval of the Product, Antares will be the exclusive provider of the Device to Teva / Sicor in accordance with the terms and conditions set forth in this Agreement, and such other
commercially reasonable terms and conditions as the Parties shall in good faith negotiate and agree to in writing including, but not limited to, specifications for the 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
Device, warranty terms, and other customary terms and conditions. Teva / Sicor will commercially market the Product incorporating the Device produced by
Antares, and Teva / Sicor will be responsible for the production of the Drug, **** the final assembly of the Product, and final packaging and labeling. 
 5.2 Forecasts and Delivery. On or before the 20th day of the third month of each calendar quarter (i.e., March 20, June 20, September 20 and December 20) Teva / Sicor will provide
Antares with a rolling quarterly forecast for the Device for the next six (6) calendar quarters. Forecasted unit demand set forth in the first two (2) quarters of each rolling quarterly forecast will represent a firm purchase commitment.
The last four (4) quarters will represent a non-binding, good faith estimate of Teva / Sicor’s expected requirements for the Device. If any rolling quarterly forecast results in a quarter-to-quarter increase of **** or more units,
or if the forecasted number of units exceeds **** units in total for any consecutive four-quarter period, the Parties agree to negotiate in good faith terms and conditions under which Antares will expand its manufacturing capacity to achieve
the incremental forecasted volumes. 
 5.2.1 Purchase Orders. With each rolling quarterly forecast, Teva / Sicor will
submit a firm purchase order for Devices needed during the second calendar quarter in the current rolling quarterly forecast. (A purchase order for Devices to be delivered in the first calendar quarter of the current rolling quarterly forecast will
have been submitted with the prior forecast.) Each purchase order must specify unit quantity, delivery dates, delivery instructions, Unit Price and other applicable invoice information as agreed by the Parties in writing (“Accepted Purchase
Order”). Changes will not be allowed to any Accepted Purchase Order unless agreed in writing by the Parties. The terms and conditions of this Agreement shall govern each purchase order, and in the event of conflict the terms and conditions of
this Agreement shall prevail. 
 5.2.2 Master Forecast. The rolling quarterly forecast submitted in September of each
calendar year shall be considered the master forecast for the following calendar year. Invoice pricing for Devices to be delivered in the next calendar year shall be determined by matching the units forecasted in the master forecast to the
corresponding Unit Price contained in the price schedule set forth in section 5.3 herein. Subject to Section 5.2.2.1 herein, should Teva / Sicor’s actual Device purchases in a calendar year differ from those set forth in the master
forecast such that a higher or lower price should have been paid, this difference shall be determined within 60 days after the end of the applicable calendar year and applied as a credit or debit against royalties payable in subsequent periods.

 5.2.2.1 No price reconciliation will be made pursuant to Section 5.2.2 as a result of; (a) increases in actual
versus forecasted volumes until after the first calendar year with at least six (6) consecutive months of commercial sales of a Product, or (b) increases in actual versus forecasted volumes due to; (i) changes in any Accepted Purchase
Order, (ii) additional purchase orders submitted for the current or next quarter after an Accepted Purchase Order exists for such quarter, or (iii) a change from Standard Pricing to Reduced Pricing. 
 5.2.3 Invoices. Teva / Sicor shall pay each invoice within thirty (30) calendar days from the date of receipt of the Devices.
Antares shall invoice Teva / Sicor at the time of shipment of the Devices to Teva / Sicor, which shall be **** 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 5.2.4 Acceptance. Antares will deliver to Teva / Sicor a certificate of
conformance with each shipment of Devices confirming that all Devices conform to the specifications. Teva / Sicor shall have forty-five (45) calendar days after the delivery date to notify Antares that Devices received were defective or
non-conforming. In such case, the parties shall use good-faith efforts to resolve the problem. 
 5.3 Standard Pricing. The Standard
Pricing for the Device supplied by Antares to Teva / Sicor will be as follows: 
       **** 
 5.4 **** 
 5.5 Adjustments to
Pricing. **** 
 5.6 Qualification of Backup Suppliers. Notwithstanding section 5.1 hereof, Teva / Sicor shall have the
right at any time during the term of this Agreement to qualify and contract with one or more backup suppliers (including Antares’ existing supplier) for the Device, in order to enable Teva / Sicor to timely exercise its rights under section 3.5
of the Agreement. Antares shall reasonably cooperate with Teva / Sicor in qualifying such backup suppliers, including, without limitation, providing appropriate technical information, subject to the execution of reasonable confidentiality
agreements. 
 5.7 **** 
 ARTICLE
6 
 REGULATORY SUBMISSIONS 
 6.1 Teva / Sicor’s Responsibilities. Teva / Sicor is responsible for preparing, prosecuting, and maintaining registrations, filings and approvals relating to the Drug and the Product, and will be responsible for its own internal
and external expenses related to regulatory submissions and approvals of the Drug and the Product. 
 6.2 Antares’
Responsibilities. Antares is responsible for preparing, prosecuting, and maintaining registrations, filings and approvals relating to the Device and will be responsible for its own internal and external expenses related to regulatory submissions
and approvals for the Device. 
 6.3 Adverse Experience Reporting. Teva / Sicor and Antares shall report to the other any information
of which they have knowledge concerning any adverse drug experience in connection with the use of the Product, including the incidence or severity thereof, whether or 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
not determined to be attributable to the Product. Reports of routine adverse drug experiences of the type defined in Section 314.80 of Title 21 of the
United States Code of Federal Regulations shall be exchanged by each Party on a quarterly basis. Reports of serious adverse drug experiences of the type defined in Sections 312.32 and 314.80 of Title 21 of the United States Code of Federal
Regulations shall be made available to the other Party within five (5) days after a Party becomes aware of such serious adverse drug experience. Upon receipt of any such information concerning any serious adverse drug experience by either Teva
/ Sicor or Antares, the Parties shall promptly consult each other and use their best efforts to arrive at a mutually acceptable procedure for taking such possible actions as appropriate or required under the circumstances; provided, however, that
nothing contained herein shall be construed as restricting the right or duty of either Party to make a required report or submission to the FDA or take any other action that it deems to be appropriate or required by applicable law or regulation. In
any event, the responsibility of making any reports of adverse drug experience or other required reports to the FDA shall be upon the holder of the product registration for the Product. 
 6.4 Recall Action. 
 6.4.1 In the event Teva / Sicor is required or voluntarily decides to initiate a recall, withdrawal, or field correction of the Product, Teva / Sicor shall notify Antares and provide a copy of its proposal, including the recall letter. In
conjunction with such recall, Antares at Teva / Sicor’s sole expense shall assist in the investigation to determine the cause and extent of the problem, unless it is subsequently determined that such recall was necessitated entirely by the
negligence or intentionally wrongful act of Antares or its representatives, in which case such assistance shall be at Antares’ sole expense. 
 6.4.2 In the event that Antares independently believes that a recall, withdrawal, or field correction of the Product may be necessary or appropriate, Antares shall notify Teva / Sicor of Antares’ belief, and the
Parties shall fully cooperate with each other concerning the necessity and nature of such action, provided that, in the event that the Product is recalled as a result of the negligent or intentionally wrongful act of Teva / Sicor or its
representatives, any expenses incurred by Antares in connection with such cooperation, including, but not limited to, outside expert fees and reasonable legal fees, shall be borne by Teva / Sicor. 
 6.4.3 All coordination of any recall, withdrawal or field correction activities involving the Product shall he handled by Teva / Sicor,
who shall keep Antares promptly advised of all matters relating thereto, whether or not such action was initially requested by Antares. Unless required by applicable law or regulation, or unless due to a defect in the Device, Teva / Sicor will not
disclose or refer to Antares in connection with a recall, withdrawal or field correction without Antares’ prior written consent. 
 6.5
Expenses. In the event that the Product is recalled as a result of the negligent or intentionally wrongful act of Teva / Sicor or its representatives, then Teva / Sicor shall bear all of the costs and expenses of such recall, including,
without limitation, expenses related to communications and meetings with all required regulatory agencies, expenses of replacement stock, the cost of notifying customers and costs associated with shipment of recalled Product from customers and
shipment of an equal amount of replacement Product to those same customers. In the event that the Product is recalled as a result of the negligent or intentionally 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
wrongful act of Antares or its representatives, then Antares shall bear all of the costs and expenses of such recall, including expenses related to
communications and meetings with all required regulatory agencies, expenses of replacement stock, the cost of notifying customers and costs associated with shipment of recalled Product from customers and shipment of an equal amount of replacement
Product to those same customers. To the extent that the reason for any recall of the Product hereunder is in part the responsibility of Antares and in part the responsibility of Teva / Sicor, then the expenses shall be equitably allocated between
the Parties. Applicable recall costs payable by Antares may be offset against future royalty payments. 
 6.6 Recall Records. Teva /
Sicor shall maintain complete and accurate recall records for such periods as may be required by applicable law, but in no event less than three (3) years, of all Product sold by it. 
 ARTICLE 7 
 ROYALTIES 
 7.1 Royalty. In consideration of the license granted pursuant to Section 3.1, Teva / Sicor shall pay Antares, **** 
 7.2 Adjustments. **** 
 7.2.1 Commercial Launch. **** 
 7.3 Taxes. All federal, state, district, local or other governmental authority
income or similar tax measured by income that is imposed on either Party as a result of income generated as a result of the transactions contemplated under this Agreement, shall be the responsibility of such Party. Any federal, state, district,
local or other governmental authority sales or use tax, excise or similar tax assessed on the sale of the Product by Teva / Sicor shall be paid by Teva / Sicor. 
 7.4 Customer Pricing. Teva / Sicor shall have sole discretion in setting customer pricing for the Product. 
 7.5 Records; Audit. Teva / Sicor shall keep books and records in the normal course of business in the Territory identifying annual (on a calendar year basis) sales of the Product in units and values, Net Sales and deductions
therefrom, gross revenue received, cost of goods sold, credits applied for returned units, and the amounts due Antares. Teva / Sicor shall maintain such books and records for two (2) years from the date of payment or until any relevant dispute
has been resolved, whichever is longer. Upon Antares’ reasonable request, and at Antares’ sole expense, but no more than once each calendar year during the term of the Agreement, Teva / Sicor shall permit an independent certified public
accountant to examine such books and records on behalf of Antares upon reasonable notice during normal business hours. Such independent certified public accountant shall sign a confidentiality and non-disclosure agreement in form and substance
reasonably satisfactory to Teva / Sicor and shall not disclose to Antares or any Third Party any information other than the amount of any inaccuracy. The report prepared by such accountant shall not disclose to Antares or to any Third Party any
information except that which should properly be contained in a royalty report required under Section 7.1 hereof and such other information as reasonably shall be necessary to verify the calculation of the Net Sales. A 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
complete copy of the report of such accountant shall be given to Teva / Sicor at the same time that it is provided to Antares. If, as a result of any such
examination, it is shown that Teva / Sicor’s payments to Antares under this Section were less than the amount which should have been paid, then Teva / Sicor shall make all payments required to be made to eliminate any discrepancy revealed by
the examination within thirty (30) days after Antares’ demand therefor and, if such discrepancy exceeds ten percent (10%) of amounts paid to Antares, Teva / Sicor shall reimburse Antares for all costs and expenses incurred by Antares
to perform the audit. The interest charged on overdue payments pursuant to Section 7.1 hereof shall apply to any underpayments due from Teva / Sicor. Any overpayments shall be fully reimbursed to Teva / Sicor within thirty (30) days after
Teva / Sicor’s demand therefor. Antares agrees that all information subject to review under this Section 7.5 or under any sublicense or supply agreement is confidential and that Antares shall retain and shall cause its accountant to retain
all such information in confidence. 
 ARTICLE 8 
 CONFIDENTIALITY 
 8.1 Confidentiality Obligation. During the term of this Agreement, and for a
period of seven (7) years following the expiration or earlier termination hereof, the receiving Party (the “Receiving Party”) will not publish or otherwise disclose to any Third Party absent an express written agreement permitting
such disclosure and will not use for any purpose other than as provided in this Agreement, any and all Confidential Information received from the other Party (the “Disclosing Party”) on a confidential basis. Each Party shall use the same
degree of care, which shall not be less than a reasonable degree of care, that it uses to protect its own confidential information to prevent the unauthorized disclosure of Confidential Information. The foregoing confidentiality obligation shall not
apply to information which: (i) at the time of the disclosure to the Receiving Party was in the public domain, or (ii) after disclosure, becomes part of the public domain through no fault of the Receiving Party or any act or omission of
the Receiving Party in breach of this Agreement, or (iii) was previously known to the Receiving Party from a source other than the Disclosing Party and such source was under no obligation to keep such information confidential or which is
received from a Third Party, provided said party did not obtain it directly or indirectly from the Disclosing Party or a party who was under a duty to keep such information confidential, or (iv) was independently developed or discovered by the
Receiving Party without the use of Confidential Information belonging to the Disclosing Party. Notwithstanding anything herein contained to the contrary, all Confidential Information previously disclosed by Antares shall continue to be subject to
the Confidential Disclosure Agreement dated December 20, 2002 between the Parties, which shall survive the execution and termination of this Agreement. 
 8.2 Authorized Disclosure. Each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary for (a) filing or prosecuting patents relating
to the Device or the Product; (b) regulatory filings; (c) prosecuting or defending litigation; (d) complying with applicable governmental regulations; (e) conducting pre-clinical or clinical trials of Products;
(f) disclosure on a need to know basis to Affiliates, sublicensees, employees, consultants or agents who agree to be bound by similar terms of confidentiality and non-use at least equivalent in scope to those set forth in this Article 8; and
(g) use of jointly owned Inventions and Technology. 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 8.3 Other Permitted Disclosure. Except as otherwise provided in Section 8.3 of this
Agreement, either Party (the “Publishing Party”) may use or refer to the name of the other Party: (i) in connection with the Publishing Party’s efforts to secure financing at any time during the term of this Agreement;
(ii) in connection with a press release regarding this Agreement and the relationship of the Parties created hereby, which shall be mutually agreed upon by the Parties; or (iii) in statements that the Publishing Party reasonably determines
to be necessary to comply with applicable law (including the disclosure requirements of the U.S. Securities and Exchange Commission or under applicable Blue Sky laws (for private financings or public financing), Nasdaq or any other stock exchange on
which securities issued by the Publishing Party are traded); provided, however, that to the extent practicable under the circumstances, the Publishing Party shall provide the other Party with a copy of the proposed text of such statements
sufficiently in advance of the scheduled release thereof to afford such other Party a reasonable opportunity to review and comment upon the proposed text. Except as permitted in this provision, neither Party shall disclose, use or refer to, without
the other Party’s prior written consent which consent shall not be unreasonably withheld or delayed, the name or trademarks of such other Party in any public statements, whether oral or written, including shareholder reports, communications
with stock market analysts or other communications with the media, or prospectuses. 
 8.4 Publications. If either Party desires to
disclose any information which relates to the Device or the Product in scientific journals, publications or scientific presentations or otherwise, the Publishing Party will provide the other Party an advance copy of any proposed publication or
summary of a proposed oral presentation prior to submission for publication or disclosure. Such other Party will have a reasonable opportunity to recommend any changes it reasonably believes necessary. 
 ARTICLE 9 
 PATENT RIGHTS 
 9.1 Ownership. ****  
 9.1.1 Securing Patent Rights. Each Party agrees to cooperate with the other in completing any patent applications and in execution and delivery of any related instruments required to secure, assign, convey or transfer the patent
rights in accordance with Section 9.1 hereof. Each Party shall promptly disclose to the other any Inventions made by employees or others acting on behalf of such Party. Teva / Sicor and Antares each hereby represents that all employees and
other Persons acting on its behalf in performing its obligations under the Agreement shall be obligated under a binding written agreement to assign to it, or as it shall direct, all intellectual property made or developed by such employees or other
Persons. Each Party shall be responsible for and shall bear all applicable costs associated with the filing, prosecution and maintenance of their respective patent rights and the Parties shall equally share in the costs directed to patent rights for
Joint Inventions with one of the Parties, upon mutual agreement, taking the lead responsibility for preparing, filing and prosecuting the application for securing patent rights for the Joint Invention. 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 9.2 Enforcement. Antares and Teva / Sicor shall promptly notify the other in writing of any
alleged or threatened infringement of the patent rights of which they become aware. Each Party shall have the right to enforce any of their respective patent rights hereunder. If either Party elects not to proceed with enforcement activity within
(i) ninety (90) days following the notice of alleged infringement or (ii) ten (10) days before any applicable time limit set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first,
then the Party owning the patent rights agrees to grant the other Party, at such other Party’s sole expense, the right to enforce the infringement rights on such Party’s behalf. In the event a Party brings an infringement action, the other
Party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney. Neither Party shall have the right to settle any patent infringement litigation under this Section 9.2 in a manner that diminishes
the rights or interests of the other Party without the express written consent of such other Party. The costs of any litigation commenced pursuant to this Section 9.2, including attorneys’ fees and expenses, shall be borne by the Party
commencing such litigation, unless the Parties agree to a different cost sharing arrangement in any particular matter. Any recovery realized by a Party commencing such litigation shall be retained by such Party. 
 Except as otherwise agreed to by the Parties as part of a cost sharing arrangement, any recovery realized or liability created as a result of such joint
litigation shall be shared equally by the Parties, after deduction of the costs of litigation incurred by the Party commencing such litigation (unless they agree beforehand to a different sharing of such recovery). 
 9.3 Third Party Infringement Actions. If Antares or Teva / Sicor or their respective customers is sued by a Third Party for infringement of a
patent because of the manufacture, use or sale of the Product, each Party promptly shall notify the other Party in writing of the institution of such suit. 
 ARTICLE 10 
 TERM AND TERMINATION 
 10.1 Term. Unless terminated earlier pursuant to the provisions hereof, this Agreement shall commence from the date of this Agreement and continue
in full force and effect until **** 
 10.2 Termination. 
 10.2.1 Termination by Either Party. Either Party may terminate this Agreement: 
 (a) upon or after the material breach of this Agreement by the other Party if that Party has not cured such breach within sixty
(60) days after receipt of written notice thereof (or fifteen (15) days in the case of nonpayment) by the nonbreaching Party; provided, however, that each Party shall have such longer period as may be needed to cure such breach, other than
for nonpayment, provided that it has promptly commenced and continues diligently to pursue such cure; 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 (b) subject to applicable bankruptcy laws, if the other Party voluntarily commences any
action or seeks any relief regarding its liquidation, reorganization, dissolution or similar act or under any bankruptcy, insolvency or similar law; or 
 (c) subject to applicable bankruptcy laws, if a proceeding is commenced or an order, judgment or decree is entered seeking the liquidation, reorganization, dissolution or similar act or any other relief under any
bankruptcy, insolvency or similar law against the other Party, without its consent, which continues undismissed or unstayed for a period of sixty (60) days. 
 10.2.2 Termination by Teva / Sicor. Teva / Sicor may terminate the Agreement **** 
 10.2.3 Termination by Antares. Antares may, at its option, terminate this Agreement ****  
 10.3 Effects of Termination. Except as otherwise provided in this Agreement, upon termination of this Agreement: 
 10.3.1 All rights, privileges and licenses granted by Antares to Teva / Sicor shall terminate and revert to Antares, and Teva / Sicor
shall not thereafter make any use whatsoever of any Confidential Information, Antares Patent Rights or Licensed Technology, provided, however, if Teva / Sicor terminates this Agreement pursuant to Sections 10.2.1(b) or (c), this Agreement may
continue in accordance with applicable bankruptcy laws. 
 **** 
 10.4 Survival. 
 10.4.1
Termination of this Agreement for any reason shall not release either Party hereto from any liability which, at the time of such termination, has already accrued to the other Party. 
 10.4.2 Notwithstanding anything herein to the contrary, either Party’s Legal Division shall be entitled to retain one archival copy
of all materials covered by Article 7 hereof, for the sole purpose of determining such Party’s ongoing confidentiality obligations. 
 10.4.3 Termination shall be the sole remedy under Section 10.2.2 hereof. 
 10.4.4 Except
as otherwise provided in Paragraph 10.4.3 hereof, termination shall not be the sole remedy under this Agreement and whether or not termination is effected all other remedies will remain available. 
 10.4.5 Articles 1, 7 **** 8, 9, 11, 12, this Section 10.4 and any obligations of a Party to make payments to the other Party
hereunder accruing prior to the termination of the Agreement, shall survive the expiration and termination of this Agreement. 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 ARTICLE 11 
 INDEMNITY 
 11.1 Indemnification by Teva / Sicor. Teva / Sicor agrees to indemnify, defend and
hold harmless Antares, its Affiliates and their respective employees against any and all Third Party claims, losses, damages and liabilities, including reasonable attorney’s fees, incurred by any of them arising out of any breach of any
obligation by Teva / Sicor hereunder, any misrepresentation by Teva / Sicor hereunder, any negligent or intentionally wrongful act or omission by Teva / Sicor in connection with the performance of this Agreement by Teva / Sicor or the manufacture or
sale of Product hereunder, or any claim that the method of production, sale or use of the Product (other than methods used under the Licensed Technology to make Device) infringes one or more claims of a patent or any trade secret or other
intellectual property right. 
 11.2 Indemnification by Antares. Antares agrees to indemnify, defend and hold harmless Teva / Sicor,
its Affiliates, and its employees against any and all Third Party claims, losses, damages and liabilities, including reasonable attorney’s fees, incurred by any of them arising out of any claim that the Device infringes one or more claims of a
patent or any trade secret or other intellectual property right, and any claim based on any misrepresentation by Antares hereunder, any negligent or intentionally wrongful act or omission by Antares in connection with the performance of this
Agreement by Antares. 
 11.3 Procedure. If Teva / Sicor, its Affiliates or their respective employees, or Antares, its Affiliates or
their respective employees (in each case an “Indemnified Party”) receive any written claim which such Indemnified Party believes is the subject of indemnity hereunder by Teva / Sicor or Antares as the case may be (in each case an
“Indemnifying Party”), the Indemnified Party shall, as soon as reasonably practicable after forming such belief, give notice thereof to the Indemnifying Party; provided, that the failure to give timely notice to the Indemnifying Party as
contemplated hereby shall not release the Indemnifying Party from any liability to the Indemnified Party unless the Indemnifying Party demonstrates that the defense of such claim is prejudiced by such failure. In case any such proceeding shall be
brought against any Indemnified Party and it shall notify the Indemnifying Party of the commencement thereof, the Indemnifying Party shall be entitled to participate therein and, to the extent that it shall wish to assume the defense thereof, with
counsel reasonably satisfactory to such Indemnified Party and shall pay as incurred the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any Indemnified Party shall have the right to retain its own counsel
at its own expense. Notwithstanding the foregoing, the Indemnifying Party shall pay as incurred (or within 30 days of presentation) the reasonable fees and expenses of the counsel retained by the Indemnified Party in the event (i) the
Indemnifying Party and the Indemnified Party shall have mutually agreed to the retention of such counsel, (ii) the named parties to any such proceeding (including any impleaded parties) include both the Indemnifying Party and the Indemnified
Party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them or (iii) the Indemnifying Party shall have failed to assume the defense and employ counsel
reasonably acceptable to the Indemnified Party within a reasonable period of time after notice of commencement of the action. It is understood that the Indemnifying Party shall not, in connection with any proceeding or related proceedings in the
same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
firm for all such indemnified parties. Such firm shall be designated in writing by Teva / Sicor in the case of parties indemnified pursuant to
Section 11.1 and by Antares in the case of parties indemnified pursuant to Section 11.2. The Indemnifying Party shall not be liable for any settlement of any proceeding effected without its written consent but if settled with such consent
or if there be a final judgment for the plaintiff, the Indemnifying Party agrees to indemnify the Indemnified Party from and against any loss or liability by reason of such settlement or judgment. In addition, the Indemnifying Party will not,
without the prior written consent of the Indemnified Party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding of which indemnification may be sought hereunder (whether or not any
Indemnified Party is an actual or potential party to such claim, action or proceeding) unless such settlement, compromise or consent includes an unconditional release of each Indemnified Party from all liability arising out of such claim, action or
proceeding. 
 11.4 Insurance. Each Party shall carry comprehensive general liability insurance, including product liability insurance
against claims for bodily injury or property damage in an amount of not less than ****. Such policy shall be endorsed to include the following: the policies shall provide for thirty (30) days’ notice to the other Party of
cancellation or material change in the coverage before such cancellation or change takes effect. Each Party shall carry the insurance coverage set forth herein during the term of this Agreement and for two (2) years following termination of
this Agreement. 
 11.5 Limitation of Liability. In no event shall either Party be liable to the other for any consequential,
incidental, special, punitive, or exemplary damages (including but not limited to loss of profits or revenues or other indirect damages), whether a claim for any such liability or damage is based upon a breach of contract, breach of warranty,
fulfillment of warranty, negligence, strict liability, misrepresentation or any other theories of liability, even if the Party has been apprised of the possibility or likelihood of such damages occurring. 
 ARTICLE 12 
 MISCELLANEOUS 

12.1 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties to the other
shall be in writing, mailed via certified mail, return receipt requested, courier or facsimile transmission, addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in writing
to the addressor and (except as otherwise provided in this Agreement) shall be effective upon receipt by the addressee or five (5) business days after dispatch. 
  

			
	If to Teva / Sicor:	  	SICOR Pharmaceuticals, Inc.
		  	19 Hughes
		  	Irvine, California 92618
		  	Attention: Senior Vice President and General Manager
		
	with a copy to:	  	Teva North America
		  	425 Privet Road
		  	Horsham, PA 19044
		  	Attention: Senior Vice President and General Counsel

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

			
	If to Antares:	  	Antares Pharma Inc.
		  	707 Eagleview Boulevard, Suite 414
		  	Exton, Pennsylvania 19341
		  	Attention: President and CEO

 12.2 Force Majeure. Neither Party shall be held liable or responsible to the other Party
nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (except the payment of money due under this Agreement) to the extent, and for so long as, such failure or
delay is caused by or results from causes beyond the reasonable control of the affected Party including fire, floods, weather conditions, embargoes, war, acts of war (whether war be declared or not), vandalism, insurrections, riots, civil
commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions, delays in acting or prohibitions by any governmental authority. The Party so affected shall give prompt notice to the other Party of such cause, and shall
take whatever steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. 
 12.3 Assignment. Except as
expressly provided hereunder, this Agreement may not be assigned or otherwise transferred, nor may any right or obligations hereunder be assigned or transferred by either Party without the consent of the other Party which may not be unreasonably
withheld or delayed; provided, however, that either may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of its business, or in the event of its
merger or consolidation or change in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. 
 12.4 Bankruptcy. If Antares files a petition in bankruptcy, or enters into an arrangement with its creditors, or applies for or consents to the appointment of a receiver or trustee or makes an assignment for
the benefit of creditors, or suffers or permits the entry of an order adjudicating it to be bankrupt or insolvent, all rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of 11 U.S.C. §101 et seq. (the “Bankruptcy Code”), licenses of rights to “intellectual property” as such term is defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that Teva /
Sicor, as a licensee of such rights under this Agreement, subject to Teva / Sicor’s compliance with its obligations under this Agreement, shall retain and may fully exercise all of its rights (including, without limitation, any right to enforce
any exclusivity provision of this Agreement, including any embodiment of such intellectual property), remedies and elections under the Bankruptcy Code. 
 12.5 Severability. Each Party hereby acknowledges that it does not intend to violate any public policy, statutory or common laws, rules, regulations, treaty or decision of any government agency or executive
body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid, the Parties shall substitute, by mutual consent, valid provisions for such invalid provisions which valid
provisions in their economic effect are sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such provisions. In case such provisions cannot be agreed upon, the
invalidity of one or several 

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to
this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions. 
 12.6 U.S. Export Laws and Regulations. Each Party hereby acknowledges that the marketing rights and information disclosure requirements of this Agreement are subject to the laws and regulations of the United States relating to the
export of products and technical information. Without limitation, each Party shall comply with all such laws and regulations. Each Party will comply with U.S. and international laws and regulations in connection with their activities required or
permitted under this Agreement including manufacturing, distribution, marketing and labeling of Products. 
 12.7 Entire Agreement.
The Agreement contains the entire understanding of the Parties with respect to the subject matter hereof. All express or implied agreements and understandings, either oral or written, heretofore made are expressly superseded by this Agreement. The
Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by both Parties. 
 12.8 Headings.
The captions to the several Articles and Sections hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. 
 12.9 Independent Contractors. It is expressly agreed that Teva / Sicor and Antares shall be independent contractors and that the relationship
between the two Parties shall not constitute a partnership, joint venture or agency. Neither Teva / Sicor nor Antares shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other, without the prior consent of the Party to be bound so. 
 12.10 Amendment and Waiver. This Agreement may be
amended, modified, superseded or cancelled and any of the terms waived, only by a written instrument executed by each Party, or in the case of a waiver, by the Parties or Party waiving compliance. The waiver by either Party of any right hereunder or
the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 
 12.11 Payments. All payments due to a Party under this Agreement shall be made in U.S. Dollars and be made by wire transfer to such Party’s
account in the depository designated from time to time by such Party. 
 12.12 No Third Party Beneficiaries. No Third Party including
any employee of any Party to this Agreement, shall have or acquire any rights by reason of this Agreement. Nothing contained in this Agreement shall be deemed to constitute the Parties partners with each other or any Third Party. 
 12.13 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. 
  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 12.14 Counterparts. The Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. Signatures may be transmitted via facsimile, thereby constituting the valid signature and delivery of this Agreement, provided original copies are
transmitted within forty-eight (48) hours to each Party after signature thereto. 
 IN WITNESS WHEREOF, the Parties have executed
this Agreement as of the date first set forth above. 
  

			
	 SICOR PHARMACEUTICALS, INC.

		
	By	 	 /s/ Mark Durand

	 Title
	 	 CFO SVP

	
	 ANTARES PHARMA INC.

		
	By	 	 /s/ Jack E. Stover

	 Title
	 	 President and CEO

  

 **** — Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]